Diligence memo · auto-generated · as of July 2, 2026

CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd looks under-valued against its niche peers and is active on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

CollPlant Biotechnologies Ltd operates in Biotech / Pharma, based in REHOVOT.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

CollPlant Biotechnologies Ltd has raised $18M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $4.5M on 2020-03-02.

Most recent recorded round closed around 2026-02-04.

Valuation (modeled)modeled

Provath models CollPlant Biotechnologies Ltd at approximately $9.9M (range $4.5M–$15M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.58× the median modeled value of Series A Biotech / Pharma companies in 2025–2027 (16 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 25 months.

Last raise 5 mo ago; this sector typically re-raises about every 15 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 1.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 74% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 33% of those peers.

Closest niche peers: Evio Pharmacy Solutions, LLC, Ruby Bio, Inc., Intelligent Bio Solutions Inc., Barnwell Bio, Inc., Arkea Bio Corp..

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.